The clinical observation of Docetaxel with weekly and 3 weekly schema combined with Capecitabine for treating metastatic breast cancer

Objective:To compare the efficacy and toxicity of Docetaxel with weekly and 3 weekly schema combined with Capecitabine for treating metastatic breast cancer.Methods:26 patients of metastatic breast cancer were given Docetaxel and Capecitabine,12 of them with weekly Docetaxel,about 25mg/m 2,d1.8.15,14 of them with 3 weekly Docetaxel,about 75mg/m 2,d1,both of them were given 1 000mg Capecitabine,twice a day for 14 days.Three weeks called one cycle.Efficacy and toxicity were evaluated.Results:In weekly group 1 patient achieved CR,3 patients achieved PR.The response rate(RR)was 33.3%,while in 3 weekly group 1 patient achieved CR,4 patients achieved PR.The response rate(RR) was 35.7%.The Ⅲ-Ⅳ grade hematologic toxicity and adverse reaction of gastrointestinal tract in 3 weekly group were higner than weekly group.While the peripheral neuritis in 3 weekly group were lower than weekly group.Conclusion:Docetaxel with Capecitabine was one of the available schemas for treating metastatic breast cancer.Differient dosage of docetaxel will achieve differient tolerance for different patients.